These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10386522)

  • 1. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide.
    Spiegelstein O; Yagen B; Bialer M
    Epilepsia; 1999 May; 40(5):545-52. PubMed ID: 10386522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity.
    abu Salach O; Hadad S; Haj-Yehia A; Sussan S; Bialer M
    Pharm Res; 1994 Oct; 11(10):1429-34. PubMed ID: 7855047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives.
    Sussan S; Dagan A; Bialer M
    Epilepsy Res; 1999 Jan; 33(1):11-21. PubMed ID: 10022362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid.
    Bialer M; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Shirvan M
    Biopharm Drug Dispos; 1996 Oct; 17(7):565-75. PubMed ID: 8894115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug.
    Isoherranen N; Woodhead JH; White HS; Bialer M
    Epilepsia; 2001 Jul; 42(7):831-6. PubMed ID: 11488880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structural requirements for the design of antiepileptic-glycine derivatives.
    Sussan S; Dagan A; Blotnik S; Bialer M
    Epilepsy Res; 1999 Apr; 34(2-3):207-20. PubMed ID: 10210036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide.
    Hadad S; Bialer M
    Biopharm Drug Dispos; 1997 Oct; 18(7):557-66. PubMed ID: 9330777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic analysis and antiepileptic activity of N-valproyl derivatives of GABA and glycine.
    Hadad S; Bialer M
    Pharm Res; 1995 Jun; 12(6):905-10. PubMed ID: 7667199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs.
    Bialer M
    J Control Release; 1999 Nov; 62(1-2):187-92. PubMed ID: 10518650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid.
    Shekh-Ahmad T; Mawasi H; McDonough JH; Finnell RH; Wlodarczyk BJ; Yavin E; Bialer M
    Epilepsia; 2014 Dec; 55(12):1944-52. PubMed ID: 25442425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The disposition of valproyl glycinamide and valproyl glycine in rats.
    Blotnik S; Bergman F; Bialer M
    Pharm Res; 1997 Jul; 14(7):873-8. PubMed ID: 9244143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography.
    Spiegelstein O; Bialer M; Yagen B
    J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):195-200. PubMed ID: 9367208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives.
    Levi M; Yagen B; Bialer M
    Pharm Res; 1997 Feb; 14(2):213-7. PubMed ID: 9090712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives.
    Mawasi H; Bibi D; Bialer M
    Bioorg Med Chem; 2016 Sep; 24(18):4246-4253. PubMed ID: 27469980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy.
    Isoherranen N; White HS; Klein BD; Roeder M; Woodhead JH; Schurig V; Yagen B; Bialer M
    Pharm Res; 2003 Aug; 20(8):1293-301. PubMed ID: 12948028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical evaluation of CHF3381 as a novel antiepileptic agent.
    Villetti G; Bregola G; Bassani F; Bergamaschi M; Rondelli I; Pietra C; Simonato M
    Neuropharmacology; 2001 Jun; 40(7):866-78. PubMed ID: 11378157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.
    Maryanoff BE; Costanzo MJ; Nortey SO; Greco MN; Shank RP; Schupsky JJ; Ortegon MP; Vaught JL
    J Med Chem; 1998 Apr; 41(8):1315-43. PubMed ID: 9548821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice.
    Isoherranen N; Yagen B; Spiegelstein O; Finnell RH; Merriweather M; Woodhead JH; Wlodarczyk B; White HS; Bialer M
    Br J Pharmacol; 2003 Jun; 139(4):755-64. PubMed ID: 12812999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic analysis and antiepileptic activity of tetra-methylcyclopropane analogues of valpromide.
    Bialer M; Hadad S; Kadry B; Abdul-Hai A; Haj-Yehia A; Sterling J; Herzig Y; Yagen B
    Pharm Res; 1996 Feb; 13(2):284-9. PubMed ID: 8932450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-(benzyloxycarbonyl)glycine esters and amides as new anticonvulsants.
    Geurts M; Poupaert JH; Scriba GK; Lambert DM
    J Med Chem; 1998 Jan; 41(1):24-30. PubMed ID: 9438018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.